α-aminoisobutyric acid, a non-proteinogenic amino acid. Its quaternary alpha carbon prevents DPP-4 from cleaving the peptide.

Do small molecules need DPP-4 protection?

No. Orforglipron and aleniglipron contain no peptide bonds, so DPP-4 has nothing to act on.

Is a DPP-4 inhibitor the same as a GLP-1 agonist?

No. An inhibitor prolongs the body's own GLP-1 into a physiological range; an agonist supplies an engineered ligand at pharmacological levels, with much larger effects.

GLP-1 & Incretin Science

DPP-4: Why Native Incretins Last Two Minutes

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Dipeptidyl peptidase-4 cleaves the first two amino acids from the N-terminus of GLP-1 and GIP, inactivating both within one to two minutes. Every long-acting incretin analogue is built to defeat this enzyme, usually by substituting the residue it recognises and adding a fatty-acid chain that binds albumin.

Key facts

Enzyme: Dipeptidyl peptidase-4 (DPP-4, CD26)
Action: Removes N-terminal dipeptide
Native GLP-1 half-life: 1–2 minutes
Cleavage site: After position 2 (Ala8 in GLP-1 numbering)
Peptide countermeasure: Aib substitution at position 8
Second countermeasure: Albumin-binding fatty diacid
Small-molecule route: No peptide bonds — not a substrate

What the enzyme does

DPP-4 is a serine exopeptidase found on cell surfaces and circulating in plasma. It removes dipeptides from the N-terminus of substrates carrying alanine or proline at the second position. GLP-1 and GIP both qualify, and both lose their receptor activity the moment those two residues are gone. The cleaved fragment is not merely weaker — it is inactive.

The first countermeasure: change the residue

If DPP-4 recognises alanine at that position, replace it with something the enzyme cannot process. Semaglutide substitutes α-aminoisobutyric acid — Aib — at position 8. Aib is a non-proteinogenic amino acid with a quaternary alpha carbon, and DPP-4 cannot accommodate it. This single change converts the peptide from a substrate into a non-substrate.

The second countermeasure: hide in plain sight

Blocking DPP-4 solves enzymatic clearance but not renal clearance, and a peptide of this size is still filtered rapidly. Attaching a fatty diacid chain that binds reversibly to serum albumin solves both: the bound complex is too large to filter and is physically shielded. Chain length tunes the result — liraglutide's C16 gives roughly daily dosing, semaglutide's C18 diacid and retatrutide's C20 diacid give weekly.

Why this is not the same as a DPP-4 inhibitor

Sitagliptin and its relatives are DPP-4 inhibitors: they block the enzyme so endogenous GLP-1 survives longer. That raises native GLP-1 into a modest physiological range. A GLP-1 receptor agonist instead supplies an engineered ligand at pharmacological concentrations. Both act on the same axis, and the difference in achievable effect size is very large.

How small molecules sidestep the whole problem

Orforglipron and aleniglipron have no peptide bonds. DPP-4 is a peptidase, and a molecule with no amide backbone is not a substrate for it in any sense — there is nothing to cleave. Neither Aib substitution nor albumin binding is needed, because the vulnerability those modifications exist to patch was never present.

Why this shapes almost every molecule in the class

Look at semaglutide, liraglutide, tirzepatide and retatrutide together and the same two features recur: a modified position-8 residue and a lipid chain for albumin binding. That is not convergent coincidence. It is four solutions to one enzyme, and it explains why these molecules look structurally similar despite differing in receptor targets.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

What is Aib?: α-aminoisobutyric acid, a non-proteinogenic amino acid. Its quaternary alpha carbon prevents DPP-4 from cleaving the peptide.
Do small molecules need DPP-4 protection?: No. Orforglipron and aleniglipron contain no peptide bonds, so DPP-4 has nothing to act on.
Is a DPP-4 inhibitor the same as a GLP-1 agonist?: No. An inhibitor prolongs the body's own GLP-1 into a physiological range; an agonist supplies an engineered ligand at pharmacological levels, with much larger effects.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum